CD34 and acute myeloid leukemia: In validation experiments with the top candidates, SLAMF6 was confirmed to be highly expressed on primitive CD34+CD38low AML cells but not on corresponding healthy hematopoietic stem and progenitor cells (HSPCs) from NBM (Fig. 1c, d).